Literature DB >> 9837798

Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.

L S Wyatt1, M W Carroll, C P Czerny, M Merchlinsky, J R Sisler, B Moss.   

Abstract

The severely attenuated and host range (HR) restricted modified vaccinia virus Ankara (MVA) was derived by >500 passages in chick embryo fibroblasts, during which multiple deletions and mutations occurred. To determine the basis of the HR defect, we prepared cosmids from the parental vaccinia virus Ankara genome and transfected them into nonpermissive monkey BS-C-1 cells that had been infected with MVA. Recombinant viruses that formed macroscopic plaques were detected after transfections with DNA segments that mapped near the left end of the viral genome. Plaque-forming viruses, generated by transfections with four individual cosmids and one pair of minimally overlapping cosmids, were purified, and their HRs were evaluated in BS-C-1 cells, rabbit RK-13 cells, and human HeLa, MRC-5, and A549 cells. The acquisition of the K1L and SPI-1 HR genes and the repair of large deletions were determined by polymerase chain reaction or pulse-field gel electrophoresis of NotI restriction enzyme digests of genomic DNA. The following results indicated the presence of previously unrecognized vaccinia virus HR genes: (1) the major mutations that restrict HR are within the left end of the MVA genome because the phenotypes of some recombinants approached that of the parental virus, (2) acquisition of the K1L gene correlated with the ability of recombinant viruses to propagate in RK-13 cells but did not enhance replication in human or monkey cell lines, (3) acquisition of the SPI-1 gene correlated with virus propagation in A549 cells but not with the extent of virus spread in monkey or other human cell lines, (4) there are at least two impaired HR genes because rescue occurred with nonoverlapping or minimally overlapping cosmids and recombinant viruses with intermediate HRs were isolated, and (5) at least one of the new HR genes did not map within any of the major deletions because the size of the left terminal NotI fragment was not appreciably altered in some recombinant viruses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837798     DOI: 10.1006/viro.1998.9397

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  35 in total

1.  Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Authors:  José Luis Nájera; Carmen Elena Gómez; Elena Domingo-Gil; María Magdalena Gherardi; Mariano Esteban
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.

Authors:  Reuben K Soi; Fred R Rurangirwa; Travis C McGuire; Paul M Rwambo; James C DeMartini; Timothy B Crawford
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

Review 3.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

4.  Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells.

Authors:  Chen Peng; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-04       Impact factor: 11.205

5.  Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Authors:  Julie Dimier; Audrey Ferrier-Rembert; Karine Pradeau-Aubreton; Matthias Hebben; Danièle Spehner; Anne-Laure Favier; Danielle Gratier; Daniel Garin; Jean-Marc Crance; Robert Drillien
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

Review 6.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

7.  Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome.

Authors:  Melissa R Ryerson; Monique M Richards; Marc Kvansakul; Christine J Hawkins; Joanna L Shisler
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

8.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

9.  Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Raquel Conde; Alberto Pascual-Montano; Keith Harshman; Mariano Esteban
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis.

Authors:  M Carmen Sancho; Sibylle Schleich; Gareth Griffiths; Jacomine Krijnse-Locker
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.